Ascendiant Capital Maintains Buy on Outlook Therapeutics, Raises Price Target to $10.5

Benzinga · 1d ago
Ascendiant Capital analyst Edward Woo maintains Outlook Therapeutics (NASDAQ:OTLK) with a Buy and raises the price target from $10 to $10.5.